Restricted accessResearch articleFirst published online 2023-02
Safety of Intravenous Administration of an AAV8 Vector Coding for an Oxidation-Resistant Human α1-Antitrypsin for the Treatment of α1-Antitrypsin Deficiency
α1-antitrypsin (AAT) deficiency is a common autosomal recessive hereditary disorder, with a high risk for the development of early-onset panacinar emphysema. AAT, produced primarily in the liver, functions to protect the lung from neutrophil protease; with AAT deficiency, unimpeded neutrophil proteases destroy the lung parenchyma. AAT is susceptible to oxidative damage resulting in an inability to inhibit its target proteases, neutrophil elastase, and cathepsin G. The major sites of oxidative modification on the AAT molecule are methionine residues 351 and 358. We have previously demonstrated that an engineered variant of AAT that resists oxidation by modifying both protein surface methionines (M351V and M358L) provides antiprotease protection, despite oxidative stress. In mice, intravenous delivery of the modified AAT(AVL) variant by AAV serotype 8, AAV8hAAT(AVL), primarily to the liver resulted in long-term expression of an AAT that resists oxidative inactivation. In this study, we evaluated the safety of intravenous administration of AAV8hAAT(AVL) in a dose-escalating, blinded, placebo-controlled toxicology study in wild-type mice. The study assessed organ histology and clinical pathology findings of mice, intravenously administered AAV8hAAT(AVL) at three doses (5.0 × 1011, 5.0 × 1012, and 5.0 × 1013 genome copies [gc]/kg), compared to control mice injected intravenously with phosphate-buffered saline. As previously demonstrated, administration of AAV8hAAT(AVL) resulted in dose-dependent expression of high, potentially therapeutic, levels of serum human AAT protein that persist for at least 6 months. Antibodies against the AAV8 capsid were elicited as expected, but there was no antibody detected against the AAT(AVL) protein generated by the AAV8hAAT(AVL) vector. There was no morbidity or mortality observed in the study. The data demonstrate that intravenous administration of AAV8hAAT(AVL) is safe with no significant adverse effect attributed to AAV8hAAT(AVL) vector at any dose. This study demonstrates that AAV8hAAT(AVL) has a safety profile consistent with the requirements for proceeding to a clinical study.
Get full access to this article
View all access options for this article.
References
1.
BrantlyM, NukiwaT, CrystalRG. Molecular basis of alpha-1-antitrypsin deficiency. Am J Med, 1988; 84:13–31.
2.
CrystalRG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest, 1990; 85:1343–1352.
3.
Group TA—ADRS. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med, 1998; 158:49–59.
de SerresFJ, BlancoI. Prevalence of alpha1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: A comprehensive review. Ther Adv Respir Dis, 2012; 6:277–295.
6.
CazzolaM, StolzD, RoglianiP, et al.α(1)-Antitrypsin deficiency and chronic respiratory disorders. Eur Respir Rev, 2020; 29:190073.
7.
GadekJE, FellsGA, ZimmermanRL, et al.Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema. J Clin Invest, 1981; 68:889–898.
8.
BrantlyML, PaulLD, MillerBH, et al.Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis, 1988; 138:327–336.
9.
GreeneCM, MillerSD, CarrollT, et al.Alpha-1 antitrypsin deficiency: A conformational disease associated with lung and liver manifestations. J Inherit Metab Dis, 2008; 31:21–34.
10.
TuderRM, JanciauskieneSM, PetracheI. Lung disease associated with alpha1-antitrypsin deficiency. Proc Am Thorac Soc, 2010; 7:381–386.
11.
AlamS, LiZ, AtkinsonC, et al.Z alpha1-antitrypsin confers a proinflammatory phenotype that contributes to chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2014; 189:909–931.
DurantonJ, BiethJG. Inhibition of proteinase 3 by [alpha]1-antitrypsin in vitro predicts very fast inhibition in vivo. Am J Respir Cell Mol Biol, 2003; 29:57–61.
14.
PetracheI, FijalkowskaI, MedlerTR, et al.a-1 Antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am J Pathol, 2006; 169:1155–1166.
15.
LungarellaG, CavarraE, LucattelliM, et al.The dual role of neutrophil elastase in lung destruction and repair. Int J Biochem Cell Biol, 2008; 40:1287–1296.
16.
CrystalRG, BrantlyML, HubbardRC, et al.The alpha 1-antitrypsin gene and its mutations. Clinical consequences and strategies for therapy. Chest, 1989; 95:196–208.
TanashHA, NilssonPM, NilssonJA, et al.Survival in severe alpha-1-antitrypsin deficiency (PiZZ). Respir Res, 2010; 11:44.
19.
GadekJE, KleinHG, HollandPV, et al.Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest, 1981; 68:1158–1165.
20.
WewersMD, CasolaroMA, SellersSE, et al.Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med, 1987; 316:1055–1062.
21.
CrystalRG. Augmentation treatment for alpha1 antitrypsin deficiency. Lancet, 2015; 386:318–320.
22.
CrystalRG. Compelling evidence for the efficacy of alpha1-antitrypsin augmentation treatment for alpha1-antitrypsin deficiency. Lancet Respir Med, 2017; 5:7–8.
23.
ChapmanKR, BurdonJG, PiitulainenE, et al.Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): A randomised, double-blind, placebo-controlled trial. Lancet, 2015; 386:360–368.
24.
BuhlR, MeyerA, VogelmeierC. Oxidant-protease interaction in the lung. Prospects for antioxidant therapy. Chest, 1996; 110:267S–272S.
25.
ElliottPR, LomasDA, CarrellRW, et al.Inhibitory conformation of the reactive loop of alpha 1-antitrypsin. Nat Struct Biol, 1996; 3:676–681.
26.
GadekJE, FellsGA, CrystalRG. Cigarette smoking induces functional antiprotease deficiency in the lower respiratory tract of humans. Science, 1979; 206:1315–1316.
27.
JanoffA, CarpH, LeeDK, et al.Cigarette smoke inhalation decreases alpha 1-antitrypsin activity in rat lung. Science, 1979; 206:1313–1314.
28.
CarpH, JanoffA. Potential mediator of inflammation. Phagocyte-derived oxidants suppress the elastase-inhibitory capacity of alpha 1-proteinase inhibitor in vitro. J Clin Invest, 1980; 66:987–995.
29.
EvansMD, PryorWA. Cigarette smoking, emphysema, and damage to alpha 1-proteinase inhibitor. Am J Physiol, 1994; 266:L593–L611.
30.
ScottLJ, RussellGI, NixonNB, et al.Oxidation of alpha1-proteinase inhibitor by the myeloperoxidase-hydrogen peroxidase system promotes binding to immunoglobulin A. Biochem Biophys Res Commun, 1999; 255:562–567.
31.
TaggartC, Cervantes-LaureanD, KimG, et al.Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity. J Biol Chem, 2000; 275:27258–27265.
32.
JohnsonD, TravisJ. The oxidative inactivation of human alpha-1-proteinase inhibitor. Further evidence for methionine at the reactive center. J Biol Chem, 1979; 254:4022–4026.
33.
MathesonNR, WongPS, TravisJ. Enzymatic inactivation of human alpha-1-proteinase inhibitor by neutrophil myeloperoxidase. Biochem Biophys Res Commun, 1979; 88:402–409.
34.
BeattyK, BiethJ, TravisJ. Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin. J Biol Chem, 1980; 255:3931–3934.
35.
SummersFA, MorganPE, DaviesMJ, et al.Identification of plasma proteins that are susceptible to thiol oxidation by hypochlorous acid and N-chloramines. Chem Res Toxicol, 2008; 21:1832–1840.
36.
TopicA, RadojkovicD. Polymerization and Oxidation of Alpha-1-Antitrypsin in Pathogenesis of Emphysema, Lung Diseases. In: Selected State of the Art Reviews. (IrusenEM. Ed.) InTech: 2012. Available from: www.intechopen.com/books/lung-diseases-selected-state-of-the-art-reviews/polymerization-and-oxidation-of-alpha-1-antitrypsin-in-pathogenesis-of-emphysema [Last accessed November29, 2022].
37.
CohenAB, JamesHL. Reduction of the elastase inhibitory capacity of alpha 1-antitrypsin by peroxides in cigarette smoke: An analysis of brands and filters. Am Rev Respir Dis, 1982; 126:25–30.
38.
AlamS, LiZ, JanciauskieneS, et al.Oxidation of Z alpha1-antitrypsin by cigarette smoke induces polymerization: A novel mechanism of early-onset emphysema. Am J Respirat Cell Mol Biol, 2011; 45:261–269.
39.
YehK, LiL, WaniaF, et al.Thirdhand smoke from tobacco, e-cigarettes, cannabis, methamphetamine and cocaine: Partitioning, reactive fate, and human exposure in indoor environments. Environ Int, 2022; 160:107063.
40.
RosenbergS, BarrPJ, NajarianRC, et al.Synthesis in yeast of a functional oxidation-resistant mutant of human alpha-antitrypsin. Nature, 1984; 312:77–80.
41.
JallatS, TessierLH, BenaventeA, et al.Antiprotease targeting: Altered specificity of alpha 1-antitrypsin by amino acid replacement at the reactive centre. Rev Fr Transfus Immunohematol, 1986; 29:287–298.
42.
DaneAP, WowroSJ, CunninghamSC, et al.Comparison of gene transfer to the murine liver following intraperitoneal and intraportal delivery of hepatotropic AAV pseudo-serotypes. Gene Ther, 2013; 20:460–464.
43.
ZhuW, LiL, DengM, et al.Oxidation-resistant and thermostable forms of alpha-1 antitrypsin from Escherichia coli inclusion bodies. FEBS Open Bio, 2018; 8:1711–1721.
44.
JanoffA, George-NascimentoC, RosenbergS. A genetically engineered, mutant human alpha-1-proteinase inhibitor is more resistant than the normal inhibitor to oxidative inactivation by chemicals, enzymes, cells, and cigarette smoke. Am Rev Respir Dis, 1986; 133:353–356.
45.
LuisettiM, PozziE, DiomedeL, et al.Alpha 1-antitrypsin variants produced by recombinant DNA: Differences in elastase inhibitory activity and resistance to oxidant agents. Int J Tissue React, 1990; 12:363–368.
46.
SilbersteinDZ, KaruppananK, AungHH, et al.An oxidation-resistant, recombinant alpha-1 antitrypsin produced in Nicotiana benthamiana. Free Radic Biol Med, 2018; 120:303–310.
47.
SosulskiML, StilesKM, FrenkEZ, et al.Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin. JCI Insight, 2020; 5:e135951.
48.
NukiwaT, SatohK, BrantlyML, et al.Identification of a second mutation in the protein-coding sequence of the Z type alpha 1-antitrypsin gene. J Biol Chem, 1986; 261:15989–15994.
49.
SeixasS, GarciaO, TrovoadaMJ, et al.Patterns of haplotype diversity within the serpin gene cluster at 14q32.1: Insights into the natural history of the alpha1-antitrypsin polymorphism. Hum Genet, 2001; 108:20–30.
50.
OttoGP, RathkolbB, OestereicherMA, et al.Clinical chemistry reference intervals for C57BL/6J, C57BL/6N, and C3HeB/FeJ mice (Mus musculus). J Am Assoc Lab Anim Sci, 2016; 55:375–386.
51.
DavidoffAM, NgCY, ZhouJ, et al.Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood, 2003; 102:480–488.
52.
DeBP, HeguyA, HackettNR, et al.High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. Mol Ther, 2006; 13:67–76.
53.
InagakiK, FuessS, StormTA, et al.Robust systemic transduction with AAV9 vectors in mice: Efficient global cardiac gene transfer superior to that of AAV8. Mol Ther, 2006; 14:45–53.
54.
WuZ, SunJ, ZhangT, et al.Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther, 2008; 16:280–289.
55.
NietupskiJB, HurlbutGD, ZieglerRJ, et al.Systemic administration of AAV8-α-galactosidase A induces humoral tolerance in nonhuman primates despite low hepatic expression. Mol Ther, 2011; 19:1999–2011.
56.
MaguireCA, CrommentuijnMH, MuD, et al.Mouse gender influences brain transduction by intravascularly administered AAV9. Mol Ther, 2013; 21:1470–1471.
57.
WangG, YoungSP, BaliD, et al.Assessment of toxicity and biodistribution of recombinant AAV8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease. Mol Ther Methods Clin Dev, 2014; 1:14018.
58.
BrantlyM, CourtneyM, CrystalRG. Repair of the secretion defect in the Z form of alpha 1-antitrypsin by addition of a second mutation. Science, 1988; 242:1700–1702.
59.
American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med, 2003; 168:818–900.
60.
StollerJK, AboussouanLS. A review of alpha1-antitrypsin deficiency. Am J Respir Crit Care Med, 2012; 185:246–259.
61.
Thomson Healthcare. Red Book: Pharmacy's Fundamental Reference. Thomson Reuters: PDR Network: Montvale, NJ; 2010.
62.
ZiegerM, BorelF, GreerC, et al.Liver-directed SERPINA1 gene therapy attenuates progression of spontaneous and tobacco smoke-induced emphysema in α1-antitrypsin null mice. Mol Ther Methods Clin Dev, 2022; 25:425–438.
63.
BernsteinJA, AlexisN, BarnesC, et al.Health effects of air pollution. J Allergy Clin Immunol, 2004; 114:1116–1123.
64.
CiencewickiJ, TrivediS, KleebergerSR. Oxidants and the pathogenesis of lung diseases. J Allergy Clin Immunol, 2008; 122:456–468.
65.
WangY, PerlmutterDH. Targeting intracellular degradation pathways for treatment of liver disease caused by alpha1-antitrypsin deficiency. Pediatr Res, 2014; 75:133–139.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
